Navigation Links
ProNAi Announces Preclinical Success for PNT2258 Therapeutic -,Curative Events in Xenograft Mice for Difficult-to-Treat,Non-Hodgkin's Lymphoma

LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - ProNAi Therapeutics, Inc., a biopharmaceutical company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi), today announced that its lead oncology therapeutic candidate, PNT2258, has successfully demonstrated preclinical in vivo efficacy in xenograft mice for a number of human cancers - including curative events for difficult-to-treat Burkitt's Lymphoma.

Dr. Richard D. Gill, President and CEO of ProNAi, said, "Team ProNAi is quite pleased with our early preclinical results for PNT2258. Particularly encouraging is the fact that PNT2258 has shown promising single agent efficacy and combination therapy efficacy and drug-dose response for multiple cancer types including both hematological and solid tumors."

He added, "However, a very exciting development was our discovery that PNT2258, in combination with Rituximab, demonstrated curative events in treating Daudi xenografts of human Burkitt's Lymphoma in mice. The antitumor effect was rapid and durable. We had 70% complete remissions in two groups of animals dosed with PNT2258 and Rituximab."

In developing its DNAi(R)-based therapy, ProNAi reports that its successful establishment of in vivo efficacy for formulated PNT2258 included:

-- Single agent efficacy for DLCL2 Xenografts of Human Non-Hodgkin's Lymphoma

-- Combination therapy efficacy with Docetaxel for Human Hormone Refractory Prostate Cancer Xenograft

-- Combination therapy with Rituximab in Daudi Xenografts of Human Burkitt's Lymphoma

ProNAi's preclinical research will proceed in 2007. Planned studies include IND-enabling toxicology and ADME studies. ProNAi will file the IND for PNT2258 later this year.

About DNAi(R)

DNAi(R) (DNA interference) is a novel approach to targeting genomic DNA using sequence-specific therapeutic oligonucleotides, employing single strands of DNA to target
'"/>




Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:9/19/2014)... Sept. 19, 2014 Harwood Feffer LLP ( ... of directors of PDL BioPharma, Inc. ("PDL" or the ... board has breached its fiduciary duties to shareholders or ... 16, 2014, the Company disclosed: "On September 11, 2014, ... firm, Ernst & Young LLP ("EY"), that it was ...
(Date:9/19/2014)... "Copay coupons," a drug manufacturer ... drugs among patients with prescription drug coverage, may now be ... report  from the Department of Health and ... anti-kickback laws prohibit suppliers from offering side-payments to ... the federal government. The report ...
(Date:9/19/2014)... , Sept. 19, 2014 Today, iHealth Lab ... from Xiaomi Ventures, Ltd. for its first institutional round ... continue expanding iHealth,s global reach, accelerate growth and innovation, ... part of the investment, Xiaomi Ventures will join iHealth,s ... of cloud infrastructure and ecommerce. "We are ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2
... LAKE, N.J. , May 10 Par Pharmaceutical ... its partner, Glenmark Generics Limited and Glenmark Generics Inc., ... & Co. Inc. that resolves patent litigation related to Glenmark,s ... ends the lawsuit involving a challenge by Glenmark which sought ...
... , May 10 /PRNewswire-Asia/ -- On April ... cases with Beijing Un-Assegai Technical &,Trade Co. Ltd. (hereinafter referred ... China , as claimant and U.S. Abbott,Laboratories (Abbott U.S.; ... by the,China International Economic and Trade Arbitration Commission (CIETAC), which,has ...
Cached Medicine Technology:Par's Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R) 2Assegai Wins Big Settlement Against ABBOTT's Subsidiary 2
(Date:9/21/2014)... Texas (PRWEB) September 21, 2014 ... (FDA) in 1996, GSK’s Flovent (fluticasone propionate) is ... It is used for the maintenance treatment of ... now available in two formulations, Diskus and HFA, ... 2004, respectively. Flovent’s active ingredient, fluticasone propionate, can ...
(Date:9/21/2014)... 21, 2014 High in the rugged ... disabled and able-bodied athletes rafted the Colorado River, rode ... course in pursuit of outdoor adventure. At the September ... World T.E.A.M. Sports, disabilities proved to be no more ... the three stage event. , Each participating team of ...
(Date:9/21/2014)... IL (PRWEB) September 21, 2014 “Cluster ... is so intense and difficult to resolve,” said Steve ... I can't think of a pain that is more ... who suffers from cluster headaches, or migraines, that medical ... on the serotonin system,” he added. , Serotonin (5-HT, ...
(Date:9/21/2014)... Faculty and staff at Garrison Forest School (GFS), ... Mills, Md., kicked off the academic year by taking a ... the first independent school to receive the bands— which calculate ... patterns— as part of a pilot program with Charm ... chain. The Vivofit bands are just one tool in a ...
(Date:9/21/2014)... 21, 2014 Top10BestSEOHosting.com, a leading ... ) and GreenGeeks are the most recommended hosting ... buy high quality hosting products. , “Don’t ... suppliers; we recommend two great hosting companies to ... believe that iPage and GreenGeeks are the most ...
Breaking Medicine News(10 mins):Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Garrison Forest School Leader in Independent School Wellness Programs 2Health News:Leading Review Website Top10BestSEOHosting.com Unveils The Best Hosting Suppliers In September 2
... and Maureen Neitz, the husband-and-wife team whose pioneering research may ... disorders, as the inaugural recipients of the Jay Pepose ,75 ... a $1 million endowment established this year through a gift ... ,74, his wife. The endowment primarily supports graduate research fellowships ...
... ... Hospital Inc. (Rutherfordton, N.C.), a management client since 1983, and Sturgis Hospital (Sturgis, ... Providers by Cleverley + Associates. , ... Brentwood, Tenn. (PRWEB) December 17, 2009 -- Quorum ...
... ... is pleased to announce its newly redesigned Web site: www.psanj.com . PSANJ is a ... as New York magazine and New Jersey Monthly. , ... New Brunswick, NJ (PRWEB) December 17, 2009 -- Plastic Surgery Arts ...
... ... underscore the important role that competent, educated CT technologists play in minimizing dose ... ... (Vocus) December 16, 2009 -- Two recent studies examining radiation doses delivered during ...
... It,s customary for the holidays to wreak havoc on healthy habits. ... short-changed and nutrition is left to chance. But according to ... the holidays without throwing wellbeing out the window. That,s why California ... to make wise choices during the holiday season and get a ...
... MIAMI, Dec. 17 Physicians Healthcare Management Group, Inc. ... it has issued its financial statements for the nine months ... on the Pink Sheets (www.pinksheets.com). , About ... Management Group, Inc. (Phyhealth) is a developer of community-based health ...
Cached Medicine News:Health News:Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis 2Health News:QHR Client Hospitals in North Carolina, Michigan Lauded for Providing Community Value 2Health News:Plastic Surgery Arts of New Jersey (PSANJ) Launches New Web Site 2Health News:Plastic Surgery Arts of New Jersey (PSANJ) Launches New Web Site 3Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 2Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 3Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 4Health News:Celebrity Fitness Trainer Valerie Waters and California Raisins Offer Advice on How to Jump Start the New You in the New Year 2Health News:Celebrity Fitness Trainer Valerie Waters and California Raisins Offer Advice on How to Jump Start the New You in the New Year 3Health News:Phyhealth Issues September 30, 2009 Financial Statements 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: